Medidata has announced that medical technology business Smith & Nephew has consolidated all of its global studies on the Medidata Rave Clinial Cloud. The company expanded its use of Rave clinical solutions and will leverage Medidata Managed Services to design and implement studies globally.
By adopting the Medidata Clinical Cloud, Smith & Nephew has created a seamless data flow from electronic data capture (EDC) to clinical trial management system (CTMS) on a single platform. This simplifies trial oversight, providing clinical operations teams with easy access and visualization of data to understand enrollment and progress of a clinical trial.
Medidata's data-driven CTMS ensures that Smith & Nephew can grow its study portfolio by breaking down data silos, allowing teams to focus on oversight activities that are critical to the success of a trial. With this new functionality clinical operations teams can:
"Our expanded partnership with Medidata will establish a consistent, unified approach to manage all our clinical trials as we expand our portfolio of advanced medical products to better the lives of patients around the world," said Andy Weymann, chief medical officer, Smith & Nehphew.
Smith & Nephew will work with Medidata's managed services team to design and build studies in the areas of orthopedics, sports medicine, and advanced wound management.
For more information, go to www.medidata.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.